Meloxicam 15 mg tablets recalled for exposure to improper storage temperatures
Cardinal Healthcare is recalling Meloxicam 15 mg tablets nationwide due to exposure to temperatures outside labeled storage conditions. No adverse events have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall without reported illnesses or injuries. The hazard involves potential product degradation from temperature exposure during storage, making this a precautionary quality-control recall.
Plain-English summary
Cardinal Healthcare is recalling Meloxicam Tablets, USP, 15 mg (NDC 69097-159-15 and related package sizes) manufactured by Cipla Ltd. and distributed nationwide. The affected batch is KA11489.
The recall was initiated because the products were exposed to temperatures outside the labeled storage conditions during manufacturing. This deviation from proper storage requirements could affect the product's quality and stability.
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) prescribed to treat pain and inflammation. No illnesses or injuries have been reported in connection with this recall.
Patients who have this medication should contact their healthcare provider or pharmacist if they have questions about whether their medication is affected or if they need to take any action.
The recalled product
- Product
- MELOXICAM (MELOXICAM)
- Brand
- MELOXICAM
- Manufacturer
- CARDINAL HEALTHCARE
- Hazard
- temperature-exposure
- product-degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Batch KA11489
UPCs (2)
- 0369097159078
- 0369097158071
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27